Artelo Biosciences, Inc.
ARTL
$7.16
-$0.15-2.05%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 41.69% | 108.51% | 54.66% | -8.04% | 19.71% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.92% | 158.49% | 25.40% | -8.11% | 17.65% |
| Operating Income | 26.92% | -158.49% | -25.40% | 8.11% | -17.65% |
| Income Before Tax | -10.27% | -175.62% | -32.39% | 4.47% | -22.94% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.27% | -175.62% | -32.39% | 4.47% | -22.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.27% | -175.62% | -32.39% | 4.47% | -22.94% |
| EBIT | 26.92% | -158.49% | -25.40% | 8.11% | -17.65% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 70.55% | -88.41% | -24.09% | 6.92% | -20.63% |
| Normalized Basic EPS | 78.77% | -78.49% | -20.18% | 10.73% | -15.44% |
| EPS Diluted | 70.55% | -88.41% | -24.09% | 6.92% | -20.63% |
| Normalized Diluted EPS | 78.77% | -78.49% | -20.18% | 10.73% | -15.44% |
| Average Basic Shares Outstanding | 274.44% | 46.28% | 6.69% | 2.63% | 1.93% |
| Average Diluted Shares Outstanding | 274.44% | 46.28% | 6.69% | 2.63% | 1.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |